GeneDx (NASDAQ:WGS) Stock Price Up 5.6%

GeneDx Holdings Corp. (NASDAQ:WGSGet Free Report) shares rose 5.6% during trading on Monday . The stock traded as high as $27.60 and last traded at $27.60. Approximately 145,791 shares were traded during trading, a decline of 62% from the average daily volume of 385,836 shares. The stock had previously closed at $26.14.

Analysts Set New Price Targets

Several brokerages have issued reports on WGS. TD Cowen lifted their price target on shares of GeneDx from $14.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Jefferies Financial Group began coverage on GeneDx in a research note on Monday, June 3rd. They set a “hold” rating and a $21.00 target price for the company. The Goldman Sachs Group boosted their price objective on GeneDx to $11.00 and gave the stock a “neutral” rating in a report on Monday, April 15th. Finally, BTIG Research raised their target price on shares of GeneDx from $19.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, June 26th.

Get Our Latest Stock Report on GeneDx

GeneDx Price Performance

The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.99 and a current ratio of 3.22. The stock has a market cap of $714.12 million, a P/E ratio of -5.38 and a beta of 2.29. The business has a 50 day simple moving average of $21.87 and a 200-day simple moving average of $11.69.

GeneDx (NASDAQ:WGSGet Free Report) last issued its quarterly earnings results on Monday, April 29th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.35. GeneDx had a negative net margin of 60.86% and a negative return on equity of 36.23%. The business had revenue of $62.42 million for the quarter, compared to analysts’ expectations of $49.80 million. On average, sell-side analysts forecast that GeneDx Holdings Corp. will post -0.92 EPS for the current year.

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 6,325 shares of the firm’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $11.04, for a total transaction of $69,828.00. Following the completion of the transaction, the chief executive officer now owns 75,869 shares in the company, valued at $837,593.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Katherine Stueland sold 6,325 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $11.04, for a total transaction of $69,828.00. Following the completion of the transaction, the chief executive officer now owns 75,869 shares in the company, valued at approximately $837,593.76. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Casdin Capital, Llc acquired 50,000 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was acquired at an average price of $23.31 per share, for a total transaction of $1,165,500.00. Following the purchase, the director now directly owns 2,753,509 shares of the company’s stock, valued at $64,184,294.79. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 175,804 shares of company stock worth $3,771,670 and have sold 21,305 shares worth $462,821. 28.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of WGS. Oracle Investment Management Inc. grew its stake in shares of GeneDx by 531.7% during the first quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock valued at $10,286,000 after acquiring an additional 948,253 shares in the last quarter. Gagnon Securities LLC raised its stake in GeneDx by 59.3% during the 1st quarter. Gagnon Securities LLC now owns 556,305 shares of the company’s stock valued at $5,079,000 after purchasing an additional 207,027 shares during the period. Gagnon Advisors LLC increased its position in GeneDx by 41.6% in the 1st quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock worth $1,930,000 after purchasing an additional 62,059 shares during the last quarter. Vanguard Group Inc. lifted its holdings in GeneDx by 4.2% in the 1st quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock worth $6,460,000 after purchasing an additional 28,678 shares during the last quarter. Finally, Thompson Davis & CO. Inc. boosted its position in shares of GeneDx by 20.8% in the first quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company’s stock valued at $220,000 after acquiring an additional 4,150 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Recommended Stories

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.